Xbrane Biopharma AB Presentation Interim Report January – June 2022

"Production for the launch of Xlucane™ in Europe Q1 2023, is being initiated"*

Martin Åmark, CEO
Solna
July 22nd, 2022

***Post expiry of originator patents**

Disclaimer

You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the “Information”). and you are therefore advised to carefully read the statements below before reading. accessing or making any other use of the Information. In accessing the Information. you agree to be bound by the following terms and conditions.
The Information does not constitute or form part of. and should not be construed as. an offer or invitation to subscribe for underwrite or otherwise acquire. any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company. nor should it or any part of it form the basis of. or be relied on in connection with. any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically. this presentation does not constitute a “prospectus” within the meaning of the U.S. Securities Act of 1933. as amended.

The Information may not be reproduced. redistributed. published or passed on to any other person. directly or in directly. in whole or in part. for any purpose. The Information is not directed to. or intended for distribution to or use by. any person or entity that is a citizen or resident of. or located in. any locality. state. country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication. release or distribution in the United States. the United Kingdom. Australia. Canada or Japan. or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation. warranty or undertaking. express or implied. is made as to. and no reliance should be placed on. the fairness. accuracy. completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and has not been. and will not be. updated to reflect material developments which may occur after the date of the presentation. The Company may alter. modify or otherwise change in any manner the content of this presentation. without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which. by their nature. will have an impact on the Company’s operations. financial position and earnings. The terms “anticipates”. “assumes”. “believes”. “can”. “could”. “estimates”. “expects”. “forecasts”. “intends”. “may”. “might”. “plans”. “should”. “projects”. “will”. “would” or. in each case. their negative. or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include. but are not limited to. implementation of the Company’s strategy and its ability to further grow. risks associated with the development and of the Company’s products. ongoing research and development. the ability to commercialize the Company’s products. technology changes and new products in the Company’s potential market and industry. the ability to develop new products. the impact of competition. changes in general economy and industry conditions and legislative. regulatory and political factors. While the Company always intends to express its best judgment when making statements about what it believes will occur in the future. and although the Company bases these statements on assumptions that it believe to be reasonable when made. these forward-looking statements are not a guarantee of its performance. and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks. uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake. and specifically decline. any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

Xbrane has a portfolio addressing €53 billion of peak reference product sales

Candidate	Reference Product	Indication	Patent Expiry	Peak sales estimate*	Development Phase	Next milestone	Commercialization Partner
Xlucane™	LUCENTIS® RANIBIZUMAB INJECTION	• Age-related macular degeneration • Diabetic macular edema, • Diabetic related retinopathy	2020/22 (US/EU)	€3.2b	Registration	H2 2022 : EU approval H2 2022: Submission of Biologics License Application in US Q1 2023: Product launch in Europe	STADA Arzneimittel BAUSCH + LOMB
BIIB801	CIMZIA® (certolizumab pegol)	• Rheumatoid arthritis • Psoriasis • Crohn's disease	2024/25 (US/EU)	€2b	Process Scale-up	2023 : Initiation of clinical trial	Biogen
Xdivane™	OPDIVO® (nivolumab)	• Multiple oncology indications including Lung, liver, head & neck, kidney, colorectal cancer and melanoma	2028/30 (US/EU)	€13b	Process development	2022 : Demonstrate analytical comparability	Oncology portfolio with potential to out-license in one deal
Xtrudane™	KEYTRUDA® (pembrolizumab)		2029/31 (US/EU)	€26b	Cell-line development	2023 : Demonstrate analytical comparability	
Xdarzane™	DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL	• Multiple Myeloma	2029/31 (US/EU)	€9b	Cell-line development		

*Evaluate Pharma

Ambition to initiate at least one new biosimilar development program per year

Xlucane™ updated timeline to launch



Xlucane™ – prospects of launch in Europe

Xlucane™ is addressing a €5.1 billion market opportunity in Europe

- Retinal VEGF inhibitor market in Europe generated sales of € 5.1 billion in 2021 – Lucentis® sales of approx. € 2 billion
- Xlucane™, one of three expected Lucentis® biosimilars to be launched
- STADA, with vast experience in biosimilars, will sell and market Xlucane™ across Europe
- Xbrane entitled to 50% of profits generated

+35% volume market share achieved at month 12 in recent biosimilar launches in Europe



Ambition to be the most attractive employer within our field

Certified as a Great Place to Work®

No of employees +30% YoY

*) *Parent Company only, previous quarters adjusted*

Equality



Managment team



International



Experience



Upcoming Capital Market Events 2022

Xbrane Capital Market Day

August 2022
(invitations within short)

13th Annual Healthcare Conference

September 2022

Interim Report January – June 2022, Financials

Company Expenses (G&A and R&D)



Total Company Expenses in the quarter was in line with last year even if the R&D costs increased somewhat and the overall G&A costs showed a decline.

The expensed R&D costs for the quarter amounted to net of SEK -52.9m (-50.1), representing 91 percent (86%) of total Operating Costs.

The R&D costs expensed in the P&L includes regulatory work and establishment of Supply Chain for Xlucane™, in addition with an expanding portfolio. More specifically, start-up costs for BII801 as well as exploratory work for the new Oncology portfolio.

Company Expenses (G&A and R&D)



Comparing “like-for-like” year-on-year, the total Operating Costs have increased with 10,2%

The total R&D costs (incl. Intangible Asset of SEK 5.7m) amount to SEK 58.6m, 90.6% of the total costs in the second quarter of 2022

Noteworthy is the reclassification of the development costs for Xlucane™ in accordance with IAS 38 that started July 1st, 2021.

During the second quarter, a total of SEK 5.7m was capitalized on the Balance Sheet, which is much lower compared to previous quarters, as expected as the development phase is coming to an end.

A total of SEK 86.2m is now capitalized on the Balance Sheet referring to Xlucane™.

Cash and Cash Equivalents

Shareholders' Equity

At the end of the second quarter 2022, Cash amounts to 250.1 MSEK.


Q&A